BIO-RAD LABORATORIES, INC.

For the period ended Mar 31, 2026. Filed Apr 30, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 30, 2026

BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In millions, except share data)

	March 31, 2026	December 31, 2025
ASSETS · (Unaudited)
Current assets:
Cash and cash equivalents	$507.2	$529.8
Short-term investments	1,057.5	1,010.9
Accounts receivable, less allowance for credit losses of $4.9 and $5.5 as of March 31, 2026 and December 31, 2025, respectively	426.2	460.6
Inventory	770.5	740.7
Prepaid expenses	150.0	136.5
Other current assets	30.7	27.7
Total current assets	2,942.1	2,906.2
Property, plant and equipment, net	527.5	539.9
Operating lease right-of-use assets	161.9	170.0
Goodwill, net	577.1	579.8
Purchased intangibles, net	166.8	174.3
Other investments	5,311.8	6,103.6
Other assets	102.8	102.7
Total assets	$9,790.0	$10,576.5

Condensed Consolidated Balance Sheets

(continued)

(In millions, except share data)

	March 31, 2026	December 31, 2025
LIABILITIES AND STOCKHOLDERS’ EQUITY · (Unaudited)
Current liabilities:
Accounts payable	$133.1	$129.0
Accrued payroll and employee benefits	148.4	172.3
Current maturities of long-term debt and notes payable	400.5	1.3
Income and other taxes payable	44.9	36.6
Current operating lease liabilities	36.2	36.1
Other current liabilities	153.9	141.7
Total current liabilities	917.0	517.0
Long-term debt, net of current maturities	802.9	1,201.7
Deferred income taxes	881.8	1,059.4
Operating lease liabilities	138.6	145.7
Other long-term liabilities	198.4	199.1
Total liabilities	2,938.7	3,122.9
Stockholders’ equity:
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none	—	—
Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,199,880 and 25,199,760 as of March 31, 2026 and December 31, 2025, respectively; shares outstanding - 21,762,498 and 21,924,284 as of March 31, 2026 and December 31, 2025, respectively	—	—
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,065,990 as of March 31, 2026 and 5,066,110 as of December 31, 2025, respectively	—	—
Additional paid-in capital	490.5	476.0
Class A treasury stock at cost, 3,437,382 and 3,275,476 shares as of March 31, 2026 and December 31, 2025, respectively	(1,053.0)	(1,009.6)
Retained earnings	7,649.2	8,176.3
Accumulated other comprehensive income (loss)	(235.4)	(189.1)
Total stockholders’ equity	6,851.3	7,453.6
Total liabilities and stockholders’ equity	$9,790.0	$10,576.5

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.